✦ LIBER ✦

Multicentric phase II trial of gemcitabine plus epirubicin plus paclitaxel as first-line chemotherapy in metastatic breast cancer

✍ Scribed by Cappuzzo, F; Mazzoni, F; Gennari, A; Donati, S; Salvadori, B; Orlandini, C; Cetto, G L; Molino, A; Galligioni, E; Mansutti, M

Book ID: 109997892
Publisher: Nature Publishing Group
Year: 2004
Tongue: English
Weight: 90 KB
Volume: 90
Category: Article
ISSN: 0007-0920
DOI: 10.1038/sj.bjc.6601518

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Weekly epirubicin plus docetaxel as firs

Weekly epirubicin plus docetaxel as first-line treatment in metastatic breast cancer

✍ Gamucci, T; D'Ottavio, A M; Magnolfi, E; Barduagni, M; Vaccaro, A; Sperduti, I; 📂 Article 📅 2007 🏛 Nature Publishing Group 🌐 English ⚖ 111 KB

Phase II multicentre randomised study of

Phase II multicentre randomised study of docetaxel plus epirubicin vs 5-fluorouracil plus epirubicin and cyclophosphamide in metastatic breast cancer

✍ Bonneterre, J; Dieras, V; Tubiana-Hulin, M; Bougnoux, P; Bonneterre, M-E; Delozi 📂 Article 📅 2004 🏛 Nature Publishing Group 🌐 English ⚖ 120 KB

Cetuximab plus gemcitabine/oxaliplatin (

Cetuximab plus gemcitabine/oxaliplatin (GEMOXCET) in first-line metastatic pancreatic cancer: a multicentre phase II study

✍ Kullmann, F; Hollerbach, S; Dollinger, M M; Harder, J; Fuchs, M; Messmann, H; Tr 📂 Article 📅 2009 🏛 Nature Publishing Group 🌐 English ⚖ 113 KB

Randomised phase II trial of gemcitabine

Randomised phase II trial of gemcitabine plus vinorelbine vs gemcitabine plus cisplatin vs gemcitabine plus capecitabine in patients with pretreated metastatic breast cancer

✍ Abenhardt, W; Tesch, H; Stemmler, H J; diGioia, D; Freier, W; Tessen, H W; Gitsc 📂 Article 📅 2011 🏛 Nature Publishing Group 🌐 English ⚖ 388 KB

A phase II study of paclitaxel plus carb

A phase II study of paclitaxel plus carboplatin as first-line chemotherapy for women with metastatic breast carcinoma

✍ Edith A. Perez; David W. Hillman; Philip J. Stella; James E. Krook; Lynn C. Hart 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 96 KB 👁 3 views

## BACKGROUND. This Phase II multicenter study evaluated the efficacy and toxicity of paclitaxel (200 mg/m 2 by 3-hour infusion) with carboplatin (area under the curve 6 mg/mL per minute) administered every 3 weeks as first-line therapy for women with metastatic breast carcinoma. ## METHODS. Eligi

Docetaxel plus epirubicin is a highly ac

Docetaxel plus epirubicin is a highly active, well-tolerated, first-line chemotherapy for metastatic breast cancer: results of a large, multicentre phase II study

✍ Serafín Morales; Antonio Lorenzo; Manuel Ramos; Pedro Ballesteros; Miguel Méndez 📂 Article 📅 2003 🏛 Springer 🌐 English ⚖ 196 KB